---
title: The Effective Treatment of Oral Helicobacter Pylori With the Success Rate of Gastric Eradication
nct_id: NCT01863823
overall_status: COMPLETED
phase: PHASE1, PHASE2
sponsor: Ameritek USA
study_type: INTERVENTIONAL
primary_condition: Oral Helicobacter Pylori
countries: China
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT01863823.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT01863823"
ct_last_update_post_date: 2013-05-29
last_seen_at: "2026-05-12T06:57:30.285Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# The Effective Treatment of Oral Helicobacter Pylori With the Success Rate of Gastric Eradication

**Official Title:** Director of Research Division

**NCT ID:** [NCT01863823](https://clinicaltrials.gov/study/NCT01863823)

## Key Facts

- **Status:** COMPLETED
- **Phase:** PHASE1, PHASE2
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 350
- **Lead Sponsor:** Ameritek USA
- **Conditions:** Oral Helicobacter Pylori
- **Start Date:** 2011-08
- **Completion Date:** 2012-09
- **CT.gov Last Update:** 2013-05-29

## Brief Summary

1. Gastric eradication has no effective on oral H. pylori infection.
2. Treatment of oral infection increase success rate of eradication on stomach infection.

## Detailed Description

Objective: The present study was aimed to explore the relationship of Helicobacter pylori(H. pylori) of the oral cavity with the success rate eradication of gastric H. pylori infection.

Study Design and Setting: 202 symptomatic and 148 asymptomatic individuals were recruited and tested using Saliva H. pylori antigen tests (HPS), H. pylori flagellin (HPF), the urea breathe test (UBT) and the polymerase chain reaction (PCR) test. Test subjects also received various treatments.

We collected data of HPS, HPF , PCR and UBT before treatment on 202 symptomatic patients and 148 asymptomatic individual groups. After drug treatment, we run HPS, HPF, PCR and UBT tests. If the tests of HPS, HPF and PCR show negative that indicate success of oral H.pylori eradication. If the test of UBT show negative that indicate success of stomach H.pyloi eradication. We also compare the suceess rate of eradication on stomach infection with and without oral H. pylori infection.

## Eligibility

- **Sex:** ALL
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

* patients with gastrointestinal complaints

Exclusion Criteria:

* patients who had taken any antibiotics and/or proton pump inhibitors within four weeks prior to sample collection
```

## Arms

- **Amoxicillin and Tetracyclines** (OTHER) — drug treatment
- **Mouth washing** (OTHER) — Mouth washing

## Interventions

- **Amoxicillin and Tetracyclines** (DRUG) — 202 symptomatic and 148 asymptomatic individuals were recruited and tested using Saliva H. pylori antigen tests (HPS), H. pylori flagellin (HPF), the urea breathe test (UBT) and the polymerase chain reaction (PCR) test. Test subjects also received various treatments.
- **Mouth washing** (DRUG) — Two time washing mouth per day

## Primary Outcomes

- **Success Rate** _(time frame: 12 months)_

## Secondary Outcomes

- **Diagnostic** _(time frame: 6 months)_

## Locations (1)

- Beijing University First Hospital, Beijiang, China

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.beijing university first hospital|beijiang||china` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT01863823.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT01863823*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*